APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceutical CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radiopharmaceutical CDMO Market Outlook and Growth Opportunities 2026

Report ID 174225770415 April 2026Not stated

Choose your research edition.

Industry ResearchRadiopharmaceutical CDMO Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceutical CDMO Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Radiopharmaceutical CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceutical CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceutical CDMO Market Analysis and Forecast 2026-2032242 pages · $4,950 USD

Market perspective

The global Radiopharmaceutical CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radiopharmaceutical CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiopharmaceutical CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceutical CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radiopharmaceutical CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radiopharmaceutical CDMO market include Almac, AtomVie, Cardinal Health, Cyclotek, Eckert & Ziegler, Seibersdorf Labor GmbH, Evergreen Theragnostics, Lantheus and Medi-Radiopharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Radiopharmaceutical CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiopharmaceutical CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceutical CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Radiopharmaceutical CDMO market.

Radiopharmaceutical CDMO Segment by Company

Almac

AtomVie

Cardinal Health

Cyclotek

Eckert & Ziegler

Seibersdorf Labor GmbH

Evergreen Theragnostics

Lantheus

Medi-Radiopharma

Minerva Imaging

NorthStar

ROTOP Pharmaka GmbH

Nucleus RadioPharma

PharmaLogic

Radiopharmaceutical CDMO Segment by Type

R&D CDMO

Production CDMO

Radiopharmaceutical CDMO Segment by Application

Diagnosis

Treatment

Radiopharmaceutical CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Radiopharmaceutical CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Radiopharmaceutical CDMO key companies, revenue, market share, and recent developments.

3. To split the Radiopharmaceutical CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Radiopharmaceutical CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiopharmaceutical CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Radiopharmaceutical CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceutical CDMO industry.

Chapter 3: Detailed analysis of Radiopharmaceutical CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Radiopharmaceutical CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Radiopharmaceutical CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceutical CDMO Industry Trends Table 2. Radiopharmaceutical CDMO Industry Drivers Table 3. Radiopharmaceutical CDMO Industry Opportunities and Challenges Table 4. Radiopharmaceutical CDMO Industry Restraints Table 5. Global Radiopharmaceutical CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceutical CDMO Revenue Share by Company (2021-2026) Table 7. Global Radiopharmaceutical CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Radiopharmaceutical CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Radiopharmaceutical CDMO Company, Product Type & Application Table 10. Global Radiopharmaceutical CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Radiopharmaceutical CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of R&D CDMO Table 15. Significant Companies of Production CDMO Table 16. Global Radiopharmaceutical CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Radiopharmaceutical CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Radiopharmaceutical CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Radiopharmaceutical CDMO Sales Value Share by Type (2021-2026) Table 20. Global Radiopharmaceutical CDMO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Diagnosis Table 22. Significant Companies of Treatment Table 23. Global Radiopharmaceutical CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Radiopharmaceutical CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Radiopharmaceutical CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Radiopharmaceutical CDMO Sales Value Share by Application (2021-2026) Table 27. Global Radiopharmaceutical CDMO Sales Value Share by Application (2027-2032) Table 28. Global Radiopharmaceutical CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Radiopharmaceutical CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Radiopharmaceutical CDMO Sales Value Share by Region (2021-2026) Table 31. Global Radiopharmaceutical CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Radiopharmaceutical CDMO Sales Value Share by Region (2027-2032) Table 33. Global Radiopharmaceutical CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Radiopharmaceutical CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Radiopharmaceutical CDMO Sales Value Market Share by Country (2021-2026) Table 36. Global Radiopharmaceutical CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Radiopharmaceutical CDMO Sales Value Market Share by Country (2027-2032) Table 38. Almac Company Information Table 39. Almac Business Overview Table 40. Almac Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Almac Radiopharmaceutical CDMO Product Portfolio Table 42. Almac Recent Development Table 43. AtomVie Company Information Table 44. AtomVie Business Overview Table 45. AtomVie Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. AtomVie Radiopharmaceutical CDMO Product Portfolio Table 47. AtomVie Recent Development Table 48. Cardinal Health Company Information Table 49. Cardinal Health Business Overview Table 50. Cardinal Health Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Cardinal Health Radiopharmaceutical CDMO Product Portfolio Table 52. Cardinal Health Recent Development Table 53. Cyclotek Company Information Table 54. Cyclotek Business Overview Table 55. Cyclotek Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Cyclotek Radiopharmaceutical CDMO Product Portfolio Table 57. Cyclotek Recent Development Table 58. Eckert & Ziegler Company Information Table 59. Eckert & Ziegler Business Overview Table 60. Eckert & Ziegler Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Eckert & Ziegler Radiopharmaceutical CDMO Product Portfolio Table 62. Eckert & Ziegler Recent Development Table 63. Seibersdorf Labor GmbH Company Information Table 64. Seibersdorf Labor GmbH Business Overview Table 65. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Portfolio Table 67. Seibersdorf Labor GmbH Recent Development Table 68. Evergreen Theragnostics Company Information Table 69. Evergreen Theragnostics Business Overview Table 70. Evergreen Theragnostics Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Evergreen Theragnostics Radiopharmaceutical CDMO Product Portfolio Table 72. Evergreen Theragnostics Recent Development Table 73. Lantheus Company Information Table 74. Lantheus Business Overview Table 75. Lantheus Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Lantheus Radiopharmaceutical CDMO Product Portfolio Table 77. Lantheus Recent Development Table 78. Medi-Radiopharma Company Information Table 79. Medi-Radiopharma Business Overview Table 80. Medi-Radiopharma Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Medi-Radiopharma Radiopharmaceutical CDMO Product Portfolio Table 82. Medi-Radiopharma Recent Development Table 83. Minerva Imaging Company Information Table 84. Minerva Imaging Business Overview Table 85. Minerva Imaging Radiopharmaceutical CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Minerva Imaging Radiopharmaceutical CDMO Product Portfolio Table 87. Minerva Imaging Recent Development Table 88. NorthStar Company Information Table 89. NorthStar Business Overview Table 90. NorthStar Radiopharmaceutical CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. NorthStar Radiopharmaceutical CDMO Product Portfolio Table 92. NorthStar Recent Development Table 93. ROTOP Pharmaka GmbH Company Information Table 94. ROTOP Pharmaka GmbH Business Overview Table 95. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Portfolio Table 97. ROTOP Pharmaka GmbH Recent Development Table 98. Nucleus RadioPharma Company Information Table 99. Nucleus RadioPharma Business Overview Table 100. Nucleus RadioPharma Radiopharmaceutical CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Nucleus RadioPharma Radiopharmaceutical CDMO Product Portfolio Table 102. Nucleus RadioPharma Recent Development Table 103. PharmaLogic Company Information Table 104. PharmaLogic Business Overview Table 105. PharmaLogic Radiopharmaceutical CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. PharmaLogic Radiopharmaceutical CDMO Product Portfolio Table 107. PharmaLogic Recent Development Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Radiopharmaceutical CDMO Product Image Figure 2. Global Radiopharmaceutical CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceutical CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceutical CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. R&D CDMO Image Figure 8. Production CDMO Image Figure 9. Global Radiopharmaceutical CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Radiopharmaceutical CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Radiopharmaceutical CDMO Sales Value Share by Type (2021-2032) Figure 12. Diagnosis Image Figure 13. Treatment Image Figure 14. Global Radiopharmaceutical CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Radiopharmaceutical CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Radiopharmaceutical CDMO Sales Value Share by Application (2021-2032) Figure 17. Global Radiopharmaceutical CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Radiopharmaceutical CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Radiopharmaceutical CDMO Sales Value (2021-2032) & (US$ Million) Figure 20. North America Radiopharmaceutical CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Radiopharmaceutical CDMO Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Radiopharmaceutical CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Radiopharmaceutical CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Radiopharmaceutical CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Radiopharmaceutical CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. South America Radiopharmaceutical CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Radiopharmaceutical CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Radiopharmaceutical CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • R&D CDMO
  • Production CDMO
Applications
  • Diagnosis
  • Treatment
Companies covered
  • Almac
  • AtomVie
  • Cardinal Health
  • Cyclotek
  • Eckert & Ziegler
  • Seibersdorf Labor GmbH
  • Evergreen Theragnostics
  • Lantheus
  • Medi-Radiopharma
  • Minerva Imaging
  • NorthStar
  • ROTOP Pharmaka GmbH
  • Nucleus RadioPharma
  • PharmaLogic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Radiopharmaceutical CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Radiopharmaceutical CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Radiopharmaceutical CDMO Market Dynamics
  1. 2.1 Radiopharmaceutical CDMO Industry Trends
  2. 2.2 Radiopharmaceutical CDMO Industry Drivers
  3. 2.3 Radiopharmaceutical CDMO Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceutical CDMO Industry Restraints
3 Radiopharmaceutical CDMO Market by Company
  1. 3.1 Global Radiopharmaceutical CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Radiopharmaceutical CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Radiopharmaceutical CDMO Company Ranking (2024-2026)
  4. 3.4 Global Radiopharmaceutical CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Radiopharmaceutical CDMO Company Product Type and Application
  6. 3.6 Global Radiopharmaceutical CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Radiopharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Radiopharmaceutical CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Radiopharmaceutical CDMO Market by Type
  1. 4.1 Radiopharmaceutical CDMO Type Introduction
  2. 4.1.1 R&D CDMO
  3. 4.1.2 Production CDMO
  4. 4.2 Global Radiopharmaceutical CDMO Sales Value by Type
  5. 4.2.1 Global Radiopharmaceutical CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Radiopharmaceutical CDMO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Radiopharmaceutical CDMO Sales Value Share by Type (2021-2032)
5 Radiopharmaceutical CDMO Market by Application
  1. 5.1 Radiopharmaceutical CDMO Application Introduction
  2. 5.1.1 Diagnosis
  3. 5.1.2 Treatment
  4. 5.2 Global Radiopharmaceutical CDMO Sales Value by Application
  5. 5.2.1 Global Radiopharmaceutical CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Radiopharmaceutical CDMO Sales Value by Application (2021-2032)
  7. 5.2.3 Global Radiopharmaceutical CDMO Sales Value Share by Application (2021-2032)
6 Radiopharmaceutical CDMO Regional Value Analysis
  1. 6.1 Global Radiopharmaceutical CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceutical CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceutical CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Radiopharmaceutical CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Radiopharmaceutical CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Radiopharmaceutical CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Radiopharmaceutical CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Radiopharmaceutical CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Radiopharmaceutical CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Radiopharmaceutical CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Radiopharmaceutical CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Radiopharmaceutical CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Radiopharmaceutical CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Radiopharmaceutical CDMO Sales Value Share by Country, 2025 VS 2032
7 Radiopharmaceutical CDMO Country-level Value Analysis
  1. 7.1 Global Radiopharmaceutical CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiopharmaceutical CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Radiopharmaceutical CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Radiopharmaceutical CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Radiopharmaceutical CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Radiopharmaceutical CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Radiopharmaceutical CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Almac
  2. 8.1.1 Almac Company Information
  3. 8.1.2 Almac Business Overview
  4. 8.1.3 Almac Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Almac Radiopharmaceutical CDMO Product Portfolio
  6. 8.1.5 Almac Recent Developments
  7. 8.2 AtomVie
  8. 8.2.1 AtomVie Company Information
  9. 8.2.2 AtomVie Business Overview
  10. 8.2.3 AtomVie Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AtomVie Radiopharmaceutical CDMO Product Portfolio
  12. 8.2.5 AtomVie Recent Developments
  13. 8.3 Cardinal Health
  14. 8.3.1 Cardinal Health Company Information
  15. 8.3.2 Cardinal Health Business Overview
  16. 8.3.3 Cardinal Health Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cardinal Health Radiopharmaceutical CDMO Product Portfolio
  18. 8.3.5 Cardinal Health Recent Developments
  19. 8.4 Cyclotek
  20. 8.4.1 Cyclotek Company Information
  21. 8.4.2 Cyclotek Business Overview
  22. 8.4.3 Cyclotek Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cyclotek Radiopharmaceutical CDMO Product Portfolio
  24. 8.4.5 Cyclotek Recent Developments
  25. 8.5 Eckert & Ziegler
  26. 8.5.1 Eckert & Ziegler Company Information
  27. 8.5.2 Eckert & Ziegler Business Overview
  28. 8.5.3 Eckert & Ziegler Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eckert & Ziegler Radiopharmaceutical CDMO Product Portfolio
  30. 8.5.5 Eckert & Ziegler Recent Developments
  31. 8.6 Seibersdorf Labor GmbH
  32. 8.6.1 Seibersdorf Labor GmbH Company Information
  33. 8.6.2 Seibersdorf Labor GmbH Business Overview
  34. 8.6.3 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Portfolio
  36. 8.6.5 Seibersdorf Labor GmbH Recent Developments
  37. 8.7 Evergreen Theragnostics
  38. 8.7.1 Evergreen Theragnostics Company Information
  39. 8.7.2 Evergreen Theragnostics Business Overview
  40. 8.7.3 Evergreen Theragnostics Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Evergreen Theragnostics Radiopharmaceutical CDMO Product Portfolio
  42. 8.7.5 Evergreen Theragnostics Recent Developments
  43. 8.8 Lantheus
  44. 8.8.1 Lantheus Company Information
  45. 8.8.2 Lantheus Business Overview
  46. 8.8.3 Lantheus Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lantheus Radiopharmaceutical CDMO Product Portfolio
  48. 8.8.5 Lantheus Recent Developments
  49. 8.9 Medi-Radiopharma
  50. 8.9.1 Medi-Radiopharma Company Information
  51. 8.9.2 Medi-Radiopharma Business Overview
  52. 8.9.3 Medi-Radiopharma Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medi-Radiopharma Radiopharmaceutical CDMO Product Portfolio
  54. 8.9.5 Medi-Radiopharma Recent Developments
  55. 8.10 Minerva Imaging
  56. 8.10.1 Minerva Imaging Company Information
  57. 8.10.2 Minerva Imaging Business Overview
  58. 8.10.3 Minerva Imaging Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Minerva Imaging Radiopharmaceutical CDMO Product Portfolio
  60. 8.10.5 Minerva Imaging Recent Developments
  61. 8.11 NorthStar
  62. 8.11.1 NorthStar Company Information
  63. 8.11.2 NorthStar Business Overview
  64. 8.11.3 NorthStar Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NorthStar Radiopharmaceutical CDMO Product Portfolio
  66. 8.11.5 NorthStar Recent Developments
  67. 8.12 ROTOP Pharmaka GmbH
  68. 8.12.1 ROTOP Pharmaka GmbH Company Information
  69. 8.12.2 ROTOP Pharmaka GmbH Business Overview
  70. 8.12.3 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Portfolio
  72. 8.12.5 ROTOP Pharmaka GmbH Recent Developments
  73. 8.13 Nucleus RadioPharma
  74. 8.13.1 Nucleus RadioPharma Company Information
  75. 8.13.2 Nucleus RadioPharma Business Overview
  76. 8.13.3 Nucleus RadioPharma Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Nucleus RadioPharma Radiopharmaceutical CDMO Product Portfolio
  78. 8.13.5 Nucleus RadioPharma Recent Developments
  79. 8.14 PharmaLogic
  80. 8.14.1 PharmaLogic Company Information
  81. 8.14.2 PharmaLogic Business Overview
  82. 8.14.3 PharmaLogic Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 PharmaLogic Radiopharmaceutical CDMO Product Portfolio
  84. 8.14.5 PharmaLogic Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst